Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733360 | 0.79 | CYP3A4 (0.60) | TSHRCYP3A4CYP2D6USP2SMN1; SMN2 | |
| SCHEMBL14338850 | 0.78 | ALOX15 (0.56) | TSHRCYP3A4CYP2D6USP2SMN1; SMN2 | |
| SCHEMBL4487346 | 0.78 | ALOX15 (0.59) | TSHRCYP3A4CYP2D6USP2SMN1; SMN2 | |
| SCHEMBL807362 | 0.76 | ALOX15 (0.58) | TSHRCYP3A4CYP2D6USP2SMN1; SMN2 | |
| SCHEMBL3015930 | 0.76 | SIGMAR1 (0.58) | TSHRCYP3A4CYP2D6SMN1; SMN2ALOX15 | |
| SCHEMBL27893519 | 0.76 | CYP3A4 (0.50) | TSHRCYP3A4CYP2D6USP2SMN1; SMN2 | |
| SCHEMBL6218968 | 0.76 | ALOX15 (0.54) | TSHRCYP3A4CYP2D6USP2SMN1; SMN2 | |
| SCHEMBL16797869 | 0.76 | CYP1A2 (0.56) | TSHRCYP3A4CYP2D6USP2SMN1; SMN2 | |
| SCHEMBL16797885 | 0.76 | EPHX2 (0.52) | TSHRCYP3A4CYP2D6USP2SMN1; SMN2 | |
| SCHEMBL19078748 | 0.76 | TSHR (0.50) | TSHRCYP3A4CYP2D6USP2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-1963315-A2 | ENZYME INHIBITORS | The Institute of Cancer Research (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | TSHR 2859/4885CYP3A4 439/4885CYP2D6 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.